Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal

Journal of Medical Economics
Pedro A LairesGlenn M Davies

Abstract

Statin monotherapy is the mainstay of low-density lipoprotein cholesterol (LDL-C) management for high cardiovascular risk patients in Portugal; however, several therapeutic options are available and predicted to have different clinical and economic impacts. The aim of this study was to evaluate the cost-effectiveness of adding ezetimibe 10 mg (EZ10) to atorvastatin 10 or 20 mg (A10/20) vs switching to rosuvastatin 10 or 20 mg (R10/20) in Portuguese patients with coronary heart disease (CHD) and/or diabetes who are currently above the LDL-C goal. A Markov model was used to describe CHD disease progression and the lifetime costs and utilities associated with each disease state were used to estimate the gains in life-years and quality-adjusted life-years (QALYs), as well as the incremental cost-effectiveness ratio (ICER), of the two treatment regimens. Model inputs, such as age, gender, and prevalence of cardiovascular risk factors of the dyslipidemic Portuguese patients were obtained from the Portuguese cohort of the Dyslipidemia International Study (DYSIS). The efficacy of each treatment regimen, the cost of drugs and of treating CHD events, and the utilities for each disease state were derived from published sources. The estima...Continue Reading

References

Jan 29, 2000·American Heart Journal·R B D'AgostinoS C Hartz
Jan 7, 2003·American Heart Journal·Kathryn A MelsopMark A Hlatky
Apr 13, 2004·American Heart Journal·Herbert SchusterUNKNOWN Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group
Jan 25, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael F BullanoVincent J Willey
Nov 10, 2009·Current Medical Research and Opinion·Erkki J O SoiniLeo Niskanen
Jun 22, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John RecklessPhilippe Brudi
Jun 15, 2011·International Journal of Computer Assisted Radiology and Surgery·Cristian A LinteTerry M Peters
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Oct 25, 2011·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·F van NootenX H Hu

❮ Previous
Next ❯

Citations

Feb 2, 2019·International Journal of Obesity : Journal of the International Association for the Study of Obesity·Lise RetatPaul Aveyard
Jun 6, 2021·International Journal of Obesity : Journal of the International Association for the Study of Obesity·D BoyersUNKNOWN REBALANCE team

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.